E
Outlook Therapeutics, Inc.
OTLK
$1.18
$0.043.51%
E
Sell
11/7/2024Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D- on 11/7/2024 due to a decline in the volatility index and total return index.
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D- on 11/7/2024 due to a decline in the volatility index and total return index.
D
Sell
10/23/2024Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D- from E+ on 10/23/2024 due to an increase in the volatility index and valuation index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D- from E+ on 10/23/2024 due to an increase in the volatility index and valuation index.
E
Sell
11/9/2023Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D- on 11/9/2023 due to a significant decline in the solvency index, total return index and volatility index. The quick ratio declined from 1 to 0.68.
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D- on 11/9/2023 due to a significant decline in the solvency index, total return index and volatility index. The quick ratio declined from 1 to 0.68.
D
Sell
3/14/2023Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/16/2023Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 2/16/2023 due to an increase in the total return index and valuation index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 2/16/2023 due to an increase in the total return index and valuation index.
D
Sell
2/8/2023Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 2/8/2023 due to a large decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.52 to 1.25, and the quick ratio declined from 1.41 to 0.88.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 2/8/2023 due to a large decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.52 to 1.25, and the quick ratio declined from 1.41 to 0.88.
D
Sell
5/16/2022Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from E+ on 05/16/2022.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from E+ on 05/04/2022.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 05/01/2022.
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index and total return index. Operating cash flow declined 22.25% from -$8.99M to -$10.99M.
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index and total return index. Operating cash flow declined 22.25% from -$8.99M to -$10.99M.
D
Sell
11/23/2021Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 11/08/2021.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 11/08/2021.
D
Sell
2/12/2021Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 2/12/2021 due to a noticeable increase in the total return index and volatility index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 2/12/2021 due to a noticeable increase in the total return index and volatility index.
D
Sell
1/15/2021Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D- from E+ on 1/15/2021 due to an increase in the total return index, valuation index and volatility index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D- from E+ on 1/15/2021 due to an increase in the total return index, valuation index and volatility index.
E
Sell
12/24/2020Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 12/24/2020 due to a substantial decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.44 to 1.69, earnings per share declined from -$0.0332 to -$0.0814, and operating cash flow declined 102.8% from -$5.96M to -$12.08M.
Outlook Therapeutics, Inc. (OTLK) was downgraded to E+ from D on 12/24/2020 due to a substantial decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.44 to 1.69, earnings per share declined from -$0.0332 to -$0.0814, and operating cash flow declined 102.8% from -$5.96M to -$12.08M.
D
Sell
12/10/2020Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 12/10/2020 due to an increase in the volatility index and total return index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 12/10/2020 due to an increase in the volatility index and total return index.
D
Sell
11/20/2020Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 11/20/2020 due to a decline in the volatility index and valuation index.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 11/20/2020 due to a decline in the volatility index and valuation index.
D
Sell
11/4/2020Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 11/4/2020 due to an increase in the volatility index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 11/4/2020 due to an increase in the volatility index.
D
Sell
10/20/2020Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 10/20/2020 due to a decline in the valuation index.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 10/20/2020 due to a decline in the valuation index.
D
Sell
6/19/2020Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 6/19/2020 due to an increase in the volatility index and total return index.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 6/19/2020 due to an increase in the volatility index and total return index.
D
Sell
6/4/2020Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 6/4/2020 due to a decline in the volatility index.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 6/4/2020 due to a decline in the volatility index.
D
Sell
5/15/2020Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 5/15/2020 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.618 to -$0.3645, and EBIT increased 22.53% from -$8.18M to -$6.34M.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 5/15/2020 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.618 to -$0.3645, and EBIT increased 22.53% from -$8.18M to -$6.34M.
D
Sell
3/27/2020Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 3/27/2020 due to a substantial decline in the growth index and total return index. EBIT declined 85.08% from -$4.42M to -$8.18M, earnings per share declined from -$0.3611 to -$0.618, and operating cash flow declined 12.8% from -$5.92M to -$6.67M.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 3/27/2020 due to a substantial decline in the growth index and total return index. EBIT declined 85.08% from -$4.42M to -$8.18M, earnings per share declined from -$0.3611 to -$0.618, and operating cash flow declined 12.8% from -$5.92M to -$6.67M.
D
Sell
12/23/2019Upgraded
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 12/23/2019 due to a large increase in the growth index and solvency index. Total revenue increased 902.66% from $583.8 to $5.85M, operating cash flow increased 42.65% from -$10.32M to -$5.92M, and EBIT increased 21.66% from -$5.64M to -$4.42M.
Outlook Therapeutics, Inc. (OTLK) was upgraded to D from D- on 12/23/2019 due to a large increase in the growth index and solvency index. Total revenue increased 902.66% from $583.8 to $5.85M, operating cash flow increased 42.65% from -$10.32M to -$5.92M, and EBIT increased 21.66% from -$5.64M to -$4.42M.
D
Sell
6/27/2019Downgrade
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 6/27/2019 due to a decline in the growth index, volatility index and total return index. Total revenue declined 39.95% from $1.07M to $641.1.
Outlook Therapeutics, Inc. (OTLK) was downgraded to D- from D on 6/27/2019 due to a decline in the growth index, volatility index and total return index. Total revenue declined 39.95% from $1.07M to $641.1.
D
Sell
5/17/2018Upgraded
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 5/17/2018 due to a large increase in the growth index and solvency index. Earnings per share increased from -$0.709 to -$0.34, and operating cash flow increased 14.21% from -$8.67M to -$7.44M.
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 5/17/2018 due to a large increase in the growth index and solvency index. Earnings per share increased from -$0.709 to -$0.34, and operating cash flow increased 14.21% from -$8.67M to -$7.44M.
D
Sell
2/20/2018Downgrade
Oncobiologics, Inc. (ONS) was downgraded to D- from D on 2/20/2018 due to a large decline in the efficiency index and growth index. Operating cash flow declined 10,952.44% from $79.9 to -$8.67M, earnings per share declined from -$0.3056 to -$0.709, and total revenue declined 73.4% from $2.9M to $771.9.
Oncobiologics, Inc. (ONS) was downgraded to D- from D on 2/20/2018 due to a large decline in the efficiency index and growth index. Operating cash flow declined 10,952.44% from $79.9 to -$8.67M, earnings per share declined from -$0.3056 to -$0.709, and total revenue declined 73.4% from $2.9M to $771.9.
D
Sell
10/26/2017Upgraded
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 10/26/2017 due to an increase in the total return index and volatility index.
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 10/26/2017 due to an increase in the total return index and volatility index.
D
Sell
9/25/2017Downgrade
Oncobiologics, Inc. (ONS) was downgraded to D- from D on 9/25/2017 due to a decline in the volatility index.
Oncobiologics, Inc. (ONS) was downgraded to D- from D on 9/25/2017 due to a decline in the volatility index.
D
Sell
9/8/2017Upgraded
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 9/8/2017 due to an increase in the volatility index.
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 9/8/2017 due to an increase in the volatility index.
D
Sell
8/16/2017Downgrade
Oncobiologics, Inc. (ONS) was downgraded to D- from D on 8/16/2017 due to a significant decline in the efficiency index, solvency index and total return index.
Oncobiologics, Inc. (ONS) was downgraded to D- from D on 8/16/2017 due to a significant decline in the efficiency index, solvency index and total return index.
D
Sell
7/5/2017Upgraded
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 7/5/2017 due to a noticeable increase in the growth index and valuation index. EBIT increased 55.63% from -$17.9M to -$7.94M, earnings per share increased from -$0.8233 to -$0.3815, and operating cash flow increased 29.64% from -$5.84M to -$4.11M.
Oncobiologics, Inc. (ONS) was upgraded to D from D- on 7/5/2017 due to a noticeable increase in the growth index and valuation index. EBIT increased 55.63% from -$17.9M to -$7.94M, earnings per share increased from -$0.8233 to -$0.3815, and operating cash flow increased 29.64% from -$5.84M to -$4.11M.
D
Sell
3/1/2017Upgraded
Oncobiologics, Inc. (ONS) was upgraded to D- from E on 3/1/2017 due to a significant increase in the efficiency index, valuation index and solvency index.
Oncobiologics, Inc. (ONS) was upgraded to D- from E on 3/1/2017 due to a significant increase in the efficiency index, valuation index and solvency index.
E
Sell
12/1/2016Upgraded
Oncobiologics, Inc. (ONS) was upgraded to E from E- on 12/1/2016 due to an increase in the total return index and valuation index.
Oncobiologics, Inc. (ONS) was upgraded to E from E- on 12/1/2016 due to an increase in the total return index and valuation index.
E
Sell
9/7/2016None
Outlook Therapeutics, Inc. (OTLK) was downgraded to E- from U on 09/07/2016.
Outlook Therapeutics, Inc. (OTLK) was downgraded to E- from U on 09/07/2016.
NASDAQ
04/08/2025 10:56AM Eastern
Quotes delayed
